CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma

CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma

Abstract Antiangiogenic therapy with bevacizumab (Bev), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is a common treatment for recurrent glioblastoma (GBM), but its survival benefit is limited. Resistance to Bev is thought to be a major cause of ineffectiveness on Bev t...

Full description

Bibliographic Details
Main Authors: Masahiro Nishikawa, Akihiro Inoue, Takanori Ohnishi, Hajime Yano, Yonehiro Kanemura, Shohei Kohno, Shiro Ohue, Saya Ozaki, Shirabe Matsumoto, Satoshi Suehiro, Yawara Nakamura, Seiji Shigekawa, Hideaki Watanabe, Riko Kitazawa, Junya Tanaka, Takeharu Kunieda
Format: Article
Language:English
Published: Wiley 2021-03-01
Series:Cancer Medicine
Subjects:
bevacizumab
CD44
glioblastoma
glioma stem cell
invasion
vascular endothelial growth factor
Online Access:https://doi.org/10.1002/cam4.3767

Internet

https://doi.org/10.1002/cam4.3767

Similar Items